The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases.

"Conflicts of interest: These authors disclose the following: Pieter C. Dorrestein is an advisor to Sirenas, Galileo, and Cybele and an advisor and co-founder of Enveda and Ometa. Amir Zarrinpar is a founder, acting chief medical officer, and equity holder of Endure Biotherapeutics. Rob Knight is an advisor to DayTwo, an advisor to and equity holder of GenCirq and Cybele, and a co-founder, advisor and equity holder of Micronoma and Biota. These relationships have been approved by University of California, San Diego. The remaining author discloses no conflicts."

"Funding Kelly A. Fogelson was funded by NIH T32 DK007202. Pieter C. Dorrestein is supported in part by U19AG063744. Amir Zarrinpar is supported by the VA Merit BLR&D Award I01 BX005707, and NIH R01 HL148801, R01 EB030134, and U01 CA265719. Rob Knight is supported in part by U19AG063744 and DP1AT010885. All authors receive institutional support from NIH P30 DK120515, P30 DK063491, P30 CA014195, and UL1 TR001442."